Work

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Year: 2018

Type: article

Study design: Clinical Trial

Abstract: The survival outcome of patients with peripheral T-cell lymphoma (PTCL) who experience relapse or progression following first-line treatment is generally very poor.[1][1] It can improve for patients who are able to receive stem cell transplantation (SCT), particularly if remission prior to

Source: Haematologica

DOI: 10.3324/haematol.2018.187617

Authors: Paolo Strati, Dai Chihara, Yasuhiro Oki, Luis E Fayad, Nathan Fowler, Loretta Nastoupil, Jorge E Romaguera, Felipe Samaniego, Naveen Garg, Lei Feng, Emily T. Wesson, Charnelle E. Ruben, Mildred D. Stafford, Yago Nieto, Issa F Khouri, Chitra Hosing, Sandra B. Horowitz, Rammurti T-. Kamble, Michelle A. Fanale

Institutions: The University of Texas MD Anderson Cancer Center, University of New Mexico, Houston Methodist, Baylor College of Medicine

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157

Funders: Houston Methodist Hospital, University of Texas MD Anderson Cancer Center, Houston Methodist Research Institute, National Cancer Institute

Awards: G1468253849, G293715275, Cancer Center Support Grant

OpenAlex ID: W2795884927

FWCI: 2.852

Cites: 14

Cited by: 27

Related to: 10